Volume: 44 Issue: 1
Year: 2024, Page: 79-88, Doi: https://doi.org/10.51248/.v44i1.4154
Received: Dec. 2, 2023 Accepted: Feb. 12, 2024 Published: May 1, 2024
Introduction and Aim: Erosive reflux disease (ERD) and Non-erosive reflux disease (NERD) are common gastrointestinal (GI) diseases in primary healthcare facilities that might result in alterations in gastric microflora. The aim was to characterize the altered composition of the gastric microflora in both groups and their effects on normal metabolic pathways.
Materials and Methods: A total of 27 individuals, consisting of 18 patients of ERD, 4 patients of NERD, and 5 controls based on the questionnaire data and clinical diagnosis. The gastric microbiome was sequenced using 16S rRNA next-generation sequencing. Gastric microbial diversity and compositions were analyzed using MicrobiomeAnalyst. Functional analysis was performed using PICRUST.
Results: Dysbiosis was observed in both ERD and NERD groups when compared to the control. Alpha diversity was found to be significant at the ACE index, at the order (p = 0.0239) and class (p = 0.019) taxonomic levels. The gastric microbiome composition at the genus level of the study groups represented a significant decrease of Gram-positive bacterial genera such as Streptococcus, Corynebacterium, and Granulicatella along with an increase of Gram-negative genera such as Helicobacter and Veillonella. Significant alterations in the metabolic pathways due to this dysbiosis were also predicted for both groups.
Conclusion: The alterations in the gastric microflora are caused by both ERD and NERD, these alterations are further associated with a shift in microbial consortia towards the abundance of gram-negative bacterial genera that might lead to the progression of GI diseases to a chronic state.
Keywords: ERD; microbiome; Helicobacter pylori; gastric cancer (GC); NERD; functional analysis
1. Shaheen, N., Ransohoff, D.F. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: Scientific review. JAMA. 2002;287(15):1972-1981.
2. Badillo, R., Francis, D. Diagnosis and treatment of gastroesophageal reflux disease. World Journal of Gastrointestinal Pharmacology and Therapeutics. 2014;(3): 105.
3. Clarrett, D.M., Hachem, C. Gastroesophageal reflux disease (GERD). Missouri Medicine. 2018;115(3):214.
4. Dieterich, W., Schink M, Zopf Y. Microbiota in the gastrointestinal tract. Medical Sciences. 2018;6(4):116.
5. Snider, E.J., Compres, G., Freedberg, D.E., Khiabanian, H., Nobel, Y.R., Stump, S., et al., Alterations to the esophageal microbiome associated with progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer Epidemiology, Biomarkers and Prevention. 2019;28(10):1687-1693.
6. Petersen, C., Round, J.L. Defining dysbiosis and its influence on host immunity and disease. Cellular MIcrobiology. 2014; 16(7):1024-1033.
7. Schubert, M.L. Gastric secretion. Current Opinion in Gastroenterology. 2005;21(6):636-643.
8. Yang, L., Lu, X., Nossa, C.W., Francois, F., Peek, R.M., Pei, Z. Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. Gastroenterology. 2009;137(2):588-597.
9. Miftahussurur, M., Doohan, D., Nusi, I.A., Adi, P., Rezkitha, Y.A., Waskito, L.A. et al., Gastroesophageal reflux disease in an area with low Helicobacter pylori infection prevalence. PloS One. 2018;13(11):e0205644.
10. Wood, M., Maton, P.N., Sorensen, S. The impact of gastroesophageal reflux disease on health-related quality of life. The American Journal of Medicine. 1998;104(3):252-258.
11. Snider, E.J., Freedberg, D.E., Abrams, J.A. Potential role of the microbiome in Barrett’s esophagus and esophageal adenocarcinoma. Digestive Diseases and Sciences. 2016; 2217- 2225.
12. Polyzos, S.A., Zeglinas, C., Artemaki, F., Doulberis, M., Kazakos, E., Katsinelos, P., et al., Helicobacter pylori infection and esophageal adenocarcinoma: A review and a personal view. Annals of Gastroenterology. 2018;31(1):8.
13. Yap, Y.A., Mariño, E. An insight into the intestinal web of mucosal immunity, microbiota, and diet in inflammation. Frontiers in Immunology. 2018;9:417660.
14. Serrano, C., Harris, P.R., Smith, P.D., Bimczok, D. Interactions between H. pylori and the gastric microbiome: Impact on gastric homeostasis and disease. Current Opinion in Physiology. 2021;21:57-64.
15. Nardone, G., Compare, D., Rocco, A. A microbiota-centric view of diseases of the upper gastrointestinal tract. The Lancet Gastroenterology and Hepatology. 2017;2(4):298-312.
16. Macfarlane, S., Furrie, E., Macfarlane, G.T., Dillon, J.F. Microbial colonization of the upper gastrointestinal tract in patients with Barrett's esophagus. Clinical Infectious Diseases. 2007;45(1):29-38.
17. Yang, F., Xie, X.H. Analysis of psychological and gut microbiome characteristics in patients with non-erosive reflux disease. Frontiers in Psychiatry. 2022;12:741049.
18. Shi, Y.C., Cai, S.T., Tian, Y.P., Zhao, H.J., Zhang, Y.B., Chen, J., et al., Effects of proton pump inhibitors on the gastrointestinal microbiota in gastroesophageal reflux disease. Genomics, Proteomics and Bioinformatics. 2019;17(1):52-63.
19. Hao, Y., Karaoz, U., Yang, L., Yachimski, P.S., Tseng, W., Nossa, C.W., et al., Progressive dysbiosis of human orodigestive microbiota along the sequence of gastroesophageal reflux, Barrett's esophagus and esophageal adenocarcinoma. International Journal of Cancer. 2022; 151(10):1703-1716.
20. Sugihartono, T., Fauzia, K.A., Miftahussurur, M., Waskito, L.A., Rejeki, P.S., I’tishom, R., et al., Analysis of gastric microbiota and Helicobacter pylori infection in gastroesophageal reflux disease. Gut pathogens. 2022;14(1): 38.
21. Smolka, A.J., Schubert, M.L. Helicobacter pylori-induced changes in gastric acid secretion and upper gastrointestinal disease. Molecular pathogenesis and signal transduction by Helicobacter pylori. 2017;227-252.
22. Pero, R., Brancaccio, M., Laneri, S., De Biasi, M.G., Lombardo, B., Scudiero, O. A novel view of human Helicobacter pylori infections: Interplay between microbiota and beta-defensins. Biomolecules. 2019;9(6):237.
23. Zhou, J., Shrestha, P., Qiu, Z., Harman, D.G., Teoh, W.C., Al-Sohaily, S., et al., Distinct microbiota dysbiosis in patients with non-erosive reflux disease and esophageal adenocarcinoma. Journal of Clinical Medicine. 2020;9(7): 2162.
24. Yuan, S., Zhang, Z.W., Li, Z.L. Antacids’ side effect hyperuricaemia could be alleviated by long-term aerobic exercise via accelerating ATP turnover rate. Biomedicine and Pharmacotherapy. 2018;99:18-24.
25. Zhao, T., Gu, D., Xu, Z., Huo, X., Shen, L., Wang, C., et al., Polymorphism in one-carbon metabolism pathway affects survival of gastric cancer patients: Large and comprehensive study. Oncotarget. 2015;6(11):9564.
26. Bi, H., Zhu, L., Jia, J., Zeng, L., Cronan, J.E. Unsaturated fatty acid synthesis in the gastric pathogen Helicobacter pylori proceeds via a backtracking mechanism. Cell Chemical Biology. 2016;23(12):1480-1489.
27. Ktsoyan, Z.A., Beloborodova, N.V., Sedrakyan, A.M., Osipov, G.A., Khachatryan, Z.A., Manukyan, G.P., et al., Profiles of microbial fatty acids in the human metabolome are disease-specific. Frontiers in Microbiology. 2011;1:8846.
28. Liu, L., Xu-Welliver, M., Kanugula, S., Pegg, A.E. Inactivation and degradation of O 6-alkylguanine-DNA alkyltransferase after reaction with nitric oxide. Cancer Research. 2002;62(11):3037-3043.
Aditya Vikram Singh, Prateek Sharma, Kunal Das, Yogendra Bhaskar, Isha Goel, Harpreet Singh, Rajashree Das. Alteration in the gastric microbiota of Erosive Reflux Disease and Non-erosive Reflux Disease patients: An indicator for disease progression. Biomedicine: 2024; 44(1): 79-88